EP2594565A3 - Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol - Google Patents

Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol Download PDF

Info

Publication number: EP2594565A3
Authority: EP; European Patent Office
Prior art keywords: subject; pharmaceutically acceptable; acceptable salt; structural formula; compound represented
Prior art date: 2007-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP13154970.1A

Other languages

German (de)

English (en)

Other versions

EP2594565A2 (fr

EP2594565B1 (fr

Inventor

Craig Siegel

Cecilia M Bastos

David J Harris

Angeles Dios

Edward Lee

Richard Silva

Lisa M Cuff

Mikaela Levine

Cassandra Celatka

Frederic Vinick

Thomas Jozefiak

Yabin Xiang

John Kane

Junkai Liao

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genzyme Corp

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-31

Filing date

2008-05-30

Publication date

2013-08-07

2008-05-30 Application filed by Genzyme Corp filed Critical Genzyme Corp

2013-05-22 Publication of EP2594565A2 publication Critical patent/EP2594565A2/fr

2013-08-07 Publication of EP2594565A3 publication Critical patent/EP2594565A3/fr

2018-10-24 Application granted granted Critical

2018-10-24 Publication of EP2594565B1 publication Critical patent/EP2594565B1/fr

Status Not-in-force legal-status Critical Current

2028-05-30 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP13154970.1A 2007-05-31 2008-05-30 Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol Not-in-force EP2594565B1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US93237007P	2007-05-31	2007-05-31
US99784607P	2007-10-05	2007-10-05
EP08768008.8A EP2167485B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
PCT/US2008/006906 WO2008150486A2 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Related Parent Applications (3)

Application Number	Title	Priority Date	Filing Date
EP08768008.8 Division		2008-05-30
EP08768008.8A Division-Into EP2167485B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP08768008.8A Division EP2167485B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Publications (3)

Publication Number	Publication Date
EP2594565A2 EP2594565A2 (fr)	2013-05-22
EP2594565A3 true EP2594565A3 (fr)	2013-08-07
EP2594565B1 EP2594565B1 (fr)	2018-10-24

Family

ID=39730765

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
EP13154967.7A Not-in-force EP2594564B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP08768008.8A Not-in-force EP2167485B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP13154949.5A Not-in-force EP2594562B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP13154970.1A Not-in-force EP2594565B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP13154955.2A Not-in-force EP2594563B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
EP13154967.7A Not-in-force EP2594564B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP08768008.8A Not-in-force EP2167485B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
EP13154949.5A Not-in-force EP2594562B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP13154955.2A Not-in-force EP2594563B1 (fr)	2007-05-31	2008-05-30	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

Country Status (4)

Country	Link
US (4)	US8304447B2 (fr)
EP (5)	EP2594564B1 (fr)
AR (1)	AR066817A1 (fr)
WO (1)	WO2008150486A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1811991B1 (fr)	2004-11-10	2018-11-07	Genzyme Corporation	Traitement du diabete de type 2 en utilisant d'inhibiteurs de la synthese des glycosphingolipides
SI2032134T1 (sl)	2006-05-09	2015-10-30	Genzyme Corporation	Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
EP2594564B1 (fr)	2007-05-31	2016-09-28	Genzyme Corporation	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
CN101888840A (zh)	2007-10-05	2010-11-17	简詹姆公司	使用脑酰胺衍生物治疗多囊性肾疾病的方法
WO2009117150A2 (fr) *	2008-03-20	2009-09-24	Genzyme Corporation	Méthode de traitement d’un lupus avec des dérivés de céramide
CA2731685A1 (fr)	2008-07-28	2010-02-04	Genzyme Corporation	Inhibition de synthase de glucosylceramide pour le traitement du glomerulopathie avec collapsus, et d'un autre trouble glomerulaire
EP3078373A1 (fr)	2008-10-03	2016-10-12	Genzyme Corporation	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
WO2010091164A1 (fr) *	2009-02-06	2010-08-12	Exelixis, Inc.	Inhibiteurs de la glucosylcéramide synthase
WO2010091104A1 (fr) *	2009-02-06	2010-08-12	Exelixis, Inc.	Inhibiteurs de la glucosylcéramide synthase
CA3140959A1 (fr) *	2009-11-27	2011-06-03	Genzyme Corporation	Forme amorphe et cristalline de genz 112638 hemitartrate comme inhibiteur de synthase de glucosylceramide
EP2543660A4 (fr) *	2010-03-04	2014-04-30	Ajinomoto Kk	Agent prophylactique ou thérapeutique pour le diabète ou l'obésité
CN102838505B (zh) *	2011-06-24	2016-02-17	上海医药工业研究院	酰胺类化合物、其制备方法及应用
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US8961959B2 (en) *	2011-10-17	2015-02-24	The Regents Of The University Of Michigan	Glucosylceramide synthase inhibitors and therapeutic methods using the same
EA201590197A1 (ru)	2012-08-23	2015-07-30	Алиос Биофарма, Инк.	Соединения для лечения парамиксовирусных вирусных инфекций
AU2014308991B2 (en)	2013-08-21	2019-02-14	Janssen Biopharma, Inc.	Antiviral compounds
JP6537500B2 (ja) *	2013-09-20	2019-07-03	ビオマリンプハルマセウトイカルインコーポレイテッド	疾患治療用のグルコシルセラミドシンターゼ阻害剤
HRP20181197T1 (hr) *	2013-10-29	2018-11-30	Biomarin Pharmaceutical Inc.	Derivati n-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamida kao inhibitori glukozilceramid sintaze
EP3164128A4 (fr) *	2014-07-03	2018-02-28	Dr. Reddy's Laboratories Ltd.	Forme amorphe d'hémitartrate d'eliglustat
WO2016126572A2 (fr)	2015-02-02	2016-08-11	The Regents Of The University Of Michigan	Inhibiteurs de la glucosylcéramide synthase et méthodes thérapeutiques les utilisant
CN107635980A (zh)	2015-03-11	2018-01-26	生物马林药物股份有限公司	用于治疗疾病的葡糖神经酰胺合酶抑制剂
MX2018006250A (es)	2015-11-18	2018-09-05	Genzyme Corp	Biomarcador de enfermedad poliquistica renal y usos del mismo.
KR20180124971A (ko)	2016-03-25	2018-11-21	젠자임 코포레이션	단백질병증의 바이오마커 및 이의 용도
JP2021506920A (ja)	2017-12-21	2021-02-22	リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌＴｈｅｒａｐｅｕｔｉｃｓＩｎｃ．	結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用
WO2020193746A1 (fr)	2019-03-28	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes de prédiction de la survie de patients atteints de mélanome
EP4048397B1 (fr)	2019-10-23	2023-08-16	The Regents Of The University Of Michigan	Inhibiteurs de la glucosylcéramide synthase pour des applications thérapeutiques
AU2020384066B2 (en)	2019-11-15	2025-10-30	Green Cross Corporation	Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
US20230002380A1 (en)	2019-11-15	2023-01-05	Yuhan Corporation	Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same
EP4142878B1 (fr)	2020-04-28	2024-06-26	The Regents of The University of Michigan	Inhibiteurs pyridine de la glucosylcéramide synthase et procédés thérapeutiques les utilisant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6051598A (en) *	1995-09-20	2000-04-18	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
WO2006053043A2 (fr) *	2004-11-10	2006-05-18	Genzyme Corporation	Methodes de traitement du diabete sucre
WO2007134086A2 (fr) *	2006-05-09	2007-11-22	Genzyme Corporation	Méthodes pour traiter une maladie de foie adipeux
WO2009045503A1 (fr) *	2007-10-05	2009-04-09	Genzyme Corporation	Procédé utilisant des dérivés de céramide pour traiter des maladies polykystiques des reins

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1555654A (en) *	1977-06-25	1979-11-14	Exxon Research Engineering Co	Agricultural burner apparatus
US4065562A (en) *	1975-12-29	1977-12-27	Nippon Shinyaku Co., Ltd.	Method and composition for reducing blood glucose levels
NO154918C (no) *	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) *	1978-05-03	1983-02-23	Nippon Shinyaku Co Ltd	Moranoline dervitives
JPS568318A (en)	1979-06-28	1981-01-28	Janssen Pharmaceutica Nv	Non oral long acting composition of haloperidol and bromperidol derivative
GB8311286D0 (en)	1983-04-26	1983-06-02	Searle & Co	Carboxyalkyl peptide derivatives
EP0144290A3 (fr) *	1983-12-01	1987-05-27	Ciba-Geigy Ag	Dérivés éthylènediamine substitués
US5041441A (en) *	1988-04-04	1991-08-20	The Regents Of The University Of Michigan	Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5302609A (en)	1992-12-16	1994-04-12	The Regents Of The University Of Michigan	Treatment of diabetic nephropathy
US5399567A (en)	1993-05-13	1995-03-21	Monsanto Company	Method of treating cholera
HUT73527A (en)	1993-08-13	1996-08-28	Seikagaku Kogyo Co Ltd	Remedy for nervous diseases
JPH09508900A (ja)	1994-02-02	1997-09-09	ザリポソームカンパニー、インコーポレーテッド	薬理学的に活性な化合物及びリポソーム並びにそれらの使用方法
US5763438A (en)	1994-06-10	1998-06-09	Seikagaku Corporation	2-acylaminopropanol compound and medical composition
US6890949B1 (en)	1999-07-09	2005-05-10	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) *	1995-09-20	2001-07-03	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en)	1995-09-20	2003-04-17	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (fr)	1999-07-09	2001-01-18	Regents Of The University Of Michigan	Composes de type amino-ceramide et procedes therapeutiques d'utilisation
JP3993908B2 (ja)	1995-12-08	2007-10-17	生化学工業株式会社	アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) *	1995-12-08	1997-06-09	Seikagaku Kogyo Kk Seikagaku C	Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja)	1995-12-20	2008-08-27	生化学工業株式会社	分化誘導作用を有する薬剤
US5972928A (en)	1997-05-21	1999-10-26	Johns Hopkins University	Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja)	1997-05-23	2008-01-23	生化学工業株式会社	アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) *	1997-06-06	2008-11-05	生化学工業株式会社	アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en)	1997-12-11	2002-10-15	Chancellor, Masters & Scholars Of The University Of Oxford	Inhibition of glycolipid biosynthesis
ATE358473T1 (de)	1998-07-27	2007-04-15	Univ Johns Hopkins	Diamino-propanol-verbindungen zur behandlung von ischaemien
US6610703B1 (en)	1998-12-10	2003-08-26	G.D. Searle & Co.	Method for treatment of glycolipid storage diseases
GB0100889D0 (en)	2001-01-12	2001-02-21	Oxford Glycosciences Uk Ltd	Compounds
US6407064B2 (en) *	1999-12-06	2002-06-18	Seikagaku Corporation	Aminoalcohol derivative and medicament comprising the same
JP5009459B2 (ja)	1999-12-06	2012-08-22	生化学工業株式会社	アミノアルコール誘導体及びそれを含有する医薬
US6235737B1 (en)	2000-01-25	2001-05-22	Peter Styczynski	Reduction of hair growth
EP1284723A4 (fr)	2000-04-19	2004-06-30	Borody Thomas J	Compositions et methodes pour traiter des troubles associes a l'hyperlipidemie
WO2002050019A2 (fr)	2000-12-20	2002-06-27	Bristol-Myers Squibb Pharma Co.	Diamines servant de modulateurs de l'activité récepteur des chimiokines
BR0116600A (pt)	2000-12-29	2004-02-10	Wyeth Corp	Método para a preparação regiosseletiva de benzo(g)quinolina-3-carbonitrilas e benzo(g)quinazolinas substituìdas
US7148251B2 (en) *	2001-01-10	2006-12-12	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en)	2001-01-10	2002-12-26	Shayman James A.	Amino ceramide - like compounds and therapeutic methods of use
US20040260099A1 (en)	2001-01-10	2004-12-23	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja)	2001-01-10	2004-10-14	ザリージェンツオブザユニバーシティオブミシガン	アミノセラミド様化合物および治療目的での使用方法
EP2067775B1 (fr)	2001-07-16	2012-04-25	Genzyme Corporation	Un inhibiteur de N-Acylsphingosine glucosyltransferase
AU2002348261A1 (en) *	2001-11-26	2003-06-10	Genzyme Corporation	Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
GB0229931D0 (en)	2002-12-21	2003-01-29	Astrazeneca Ab	Therapeutic agents
WO2003057874A1 (fr)	2001-12-28	2003-07-17	Sumitomo Pharmaceuticals Company, Limited	Marqueurs de maladies pour maladies renales et leur utilisation
EP1336411A1 (fr)	2002-02-14	2003-08-20	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Compositions et méthodes pour améliorer la thérapie de remplacement d'enzymes des maladies lysosomales
JP2003238410A (ja)	2002-02-21	2003-08-27	Seibutsu Yuki Kagaku Kenkyusho:Kk	インスリン抵抗性解除剤
US20060217560A1 (en)	2002-04-29	2006-09-28	Shayman James A	Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) *	2002-04-29	2005-07-12	Genzyme Corporation	Amino ceramide-like compounds and therapeutic methods of use
NZ538217A (en)	2002-07-17	2007-04-27	Biogen Idec Inc	Beta interferon when used to treat proteinuria, glomerular cell proliferation and inflammation
AU2003246942B2 (en)	2002-07-17	2009-06-25	Idorsia Pharmaceuticals Ltd	Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003225670A1 (en)	2003-02-28	2004-09-28	Intermune, Inc.	Interferon drug therapy for the treatment of viral diseases and liver fibrosis
GB0313678D0 (en) *	2003-06-13	2003-07-16	Oxford Glycosciences Uk Ltd	Novel compounds
EP1528056A1 (fr)	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Dérives de desoxynojirimycine et leurs utilisations en tant qu'inhibiteurs de glucosylceramidase
WO2005039578A2 (fr)	2003-10-29	2005-05-06	Macrozyme B.V.	Utilisation de derive desoxynojirimycine ou de l'un de ses sels pharmaceutiquement admis
CA2548313A1 (fr)	2003-12-23	2005-07-14	Musc Foundation For Research Development	Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
GB0400812D0 (en)	2004-01-14	2004-02-18	Celltech R&D Ltd	Novel compounds
EP1576894A1 (fr)	2004-03-16	2005-09-21	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Utilisation de sphingolipides pour la prevention et le traitement diabete deType 2, la resistance a l'insuline et syndrome metabolique
AU2005220692A1 (en)	2004-03-16	2005-09-22	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
EP1743033B1 (fr)	2004-05-07	2011-10-19	Merck Patent GmbH	Gm3 synthase utilisee comme cible therapeutique dans des complications microvasculaires du diabete
US20090111812A1 (en)	2004-06-14	2009-04-30	Musc Foundation For Research Development	Methods for treating inflammatory disorders
KR20070085232A (ko)	2004-08-20	2007-08-27	더 존스 홉킨스 유니버시티	혈관신생 치료방법
US20090088433A1 (en)	2005-01-26	2009-04-02	Bertrand Leblond	Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8389472B2 (en)	2005-08-19	2013-03-05	Amylin Pharmaceuticals, Llc	Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2008011487A2 (fr)	2006-07-19	2008-01-24	Allergan, Inc.	Procédés pour le traitement de la douleur chronique à l'aide de 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, d'amides d'acide 3-benzyl-3-hydroxy-2-amino-propioniques et de composés apparentés
WO2008011478A2 (fr)	2006-07-19	2008-01-24	Allergan, Inc.	Procédés de traitement de douleur chronique utilisant des amides d'acide 3-aryl-3-hydroxy-2-amino-propioniques, amides d'acide 3-hétéroaryl-3-hydroxy-2-amino-propionique et composés connexes
GB0614947D0 (en)	2006-07-27	2006-09-06	Isis Innovation	Epitope reduction therapy
TWI389895B (zh) *	2006-08-21	2013-03-21	Infinity Discovery Inc	抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
MX2009008493A (es)	2007-02-09	2009-08-20	Irm Llc	Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
EP2594564B1 (fr)	2007-05-31	2016-09-28	Genzyme Corporation	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
WO2009117150A2 (fr) *	2008-03-20	2009-09-24	Genzyme Corporation	Méthode de traitement d’un lupus avec des dérivés de céramide
CA2731685A1 (fr)	2008-07-28	2010-02-04	Genzyme Corporation	Inhibition de synthase de glucosylceramide pour le traitement du glomerulopathie avec collapsus, et d'un autre trouble glomerulaire
EP3078373A1 (fr)	2008-10-03	2016-10-12	Genzyme Corporation	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol

2008
- 2008-05-30 EP EP13154967.7A patent/EP2594564B1/fr not_active Not-in-force
- 2008-05-30 WO PCT/US2008/006906 patent/WO2008150486A2/fr not_active Ceased
- 2008-05-30 EP EP08768008.8A patent/EP2167485B1/fr not_active Not-in-force
- 2008-05-30 EP EP13154949.5A patent/EP2594562B1/fr not_active Not-in-force
- 2008-05-30 US US12/601,871 patent/US8304447B2/en not_active Expired - Fee Related
- 2008-05-30 EP EP13154970.1A patent/EP2594565B1/fr not_active Not-in-force
- 2008-05-30 EP EP13154955.2A patent/EP2594563B1/fr not_active Not-in-force
- 2008-06-02 AR ARP080102322A patent/AR066817A1/es active IP Right Grant
2012
- 2012-08-27 US US13/595,349 patent/US8940776B2/en not_active Expired - Fee Related
2014
- 2014-12-16 US US14/571,922 patent/US9745294B2/en not_active Expired - Fee Related
2017
- 2017-07-13 US US15/649,128 patent/US20180093981A1/en not_active Abandoned

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6051598A (en) *	1995-09-20	2000-04-18	The Regents Of The University Of Michigan	Amino ceramide-like compounds and therapeutic methods of use
WO2006053043A2 (fr) *	2004-11-10	2006-05-18	Genzyme Corporation	Methodes de traitement du diabete sucre
WO2007134086A2 (fr) *	2006-05-09	2007-11-22	Genzyme Corporation	Méthodes pour traiter une maladie de foie adipeux
WO2009045503A1 (fr) *	2007-10-05	2009-04-09	Genzyme Corporation	Procédé utilisant des dérivés de céramide pour traiter des maladies polykystiques des reins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ALBERTI, CARLO GIUSEPPE: "Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols", XP002495477, retrieved from STN Database accession no. 1957:17088 *
GAZZETTA CHIMICA ITALIANA , 86, 240-9 CODEN: GCITA9; ISSN: 0016-5603, 1956 *
JIMBO ET AL: "Development of a new inhibitor of glucosylceramide synthase", JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485 - 491, XP002372070, ISSN: 0021-924X *

Also Published As

Publication number	Publication date
EP2594563B1 (fr)	2018-07-18
US20100256216A1 (en)	2010-10-07
WO2008150486A3 (fr)	2009-02-05
US9745294B2 (en)	2017-08-29
US20120322787A1 (en)	2012-12-20
HK1185341A1 (en)	2014-02-14
US20180093981A1 (en)	2018-04-05
EP2594563A2 (fr)	2013-05-22
EP2594562B1 (fr)	2016-07-20
US20150225393A1 (en)	2015-08-13
EP2594562A2 (fr)	2013-05-22
EP2594562A3 (fr)	2013-08-14
EP2594563A3 (fr)	2013-08-07
EP2167485B1 (fr)	2015-09-30
EP2594565A2 (fr)	2013-05-22
US8940776B2 (en)	2015-01-27
EP2594565B1 (fr)	2018-10-24
EP2167485A2 (fr)	2010-03-31
EP2594564A3 (fr)	2013-08-21
HK1185076A1 (en)	2014-02-07
US8304447B2 (en)	2012-11-06
AR066817A1 (es)	2009-09-16
EP2594564B1 (fr)	2016-09-28
EP2594564A2 (fr)	2013-05-22
HK1138282A1 (zh)	2010-08-20
WO2008150486A2 (fr)	2008-12-11

Legal Events

Date	Code	Title	Description
2013-05-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-05-22	AC	Divisional application: reference to earlier application	Ref document number: 2167485 Country of ref document: EP Kind code of ref document: P
2013-05-22	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2013-07-05	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2013-07-17	RIN1	Information on inventor provided before grant (corrected)	Inventor name: DIOS, ANGELES Inventor name: LEVINE, MIKAELA Inventor name: LEE, EDWARD Inventor name: CELATKA, CASSANDRA Inventor name: VINICK, FREDERIC Inventor name: HARRIS, DAVID J Inventor name: KANE, JOHN Inventor name: BASTOS, CECILIA M Inventor name: LIAO, JUNKAI Inventor name: JOZEFIAK, THOMAS Inventor name: XIANG, YABIN Inventor name: SIEGEL, CRAIG Inventor name: SILVA, RICHARD Inventor name: CUFF, LISA M
2013-07-24	RIN1	Information on inventor provided before grant (corrected)	Inventor name: DIOS, ANGELES Inventor name: SIEGEL, CRAIG Inventor name: XIANG, YABIN Inventor name: CUFF, LISA M Inventor name: KANE, JOHN Inventor name: CELATKA, CASSANDRA Inventor name: SILVA, RICHARD Inventor name: LIAO, JUNKAI Inventor name: LEVINE, MIKAELA Inventor name: HARRIS, DAVID J Inventor name: VINICK, FREDERIC Inventor name: JOZEFIAK, THOMAS Inventor name: LEE, EDWARD Inventor name: BASTOS, CECILIA M
2013-08-07	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2013-08-07	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 405/12 20060101ALI20130704BHEP Ipc: C07D 319/18 20060101AFI20130704BHEP Ipc: C07D 411/12 20060101ALI20130704BHEP Ipc: A61K 31/357 20060101ALI20130704BHEP Ipc: C07D 295/125 20060101ALI20130704BHEP Ipc: C07D 413/12 20060101ALI20130704BHEP Ipc: C07D 405/06 20060101ALI20130704BHEP Ipc: A61P 3/10 20060101ALI20130704BHEP Ipc: C07D 409/12 20060101ALI20130704BHEP Ipc: C07D 413/14 20060101ALI20130704BHEP Ipc: C07D 409/14 20060101ALI20130704BHEP Ipc: C07D 407/12 20060101ALI20130704BHEP
2014-02-07	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1185075 Country of ref document: HK
2014-03-19	17P	Request for examination filed	Effective date: 20140207
2014-03-19	RBV	Designated contracting states (corrected)	Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2015-12-09	17Q	First examination report despatched	Effective date: 20151104
2016-11-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-05-14	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-05-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-06-13	INTG	Intention to grant announced	Effective date: 20180515
2018-07-18	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: GENZYME CORPORATION
2018-09-17	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2018-09-21	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2018-09-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2018-10-24	AC	Divisional application: reference to earlier application	Ref document number: 2167485 Country of ref document: EP Kind code of ref document: P
2018-10-24	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
2018-10-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2018-11-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2018-11-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1056506 Country of ref document: AT Kind code of ref document: T Effective date: 20181115
2018-11-22	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602008057621 Country of ref document: DE
2019-02-27	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20181024
2019-03-12	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-03-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1056506 Country of ref document: AT Kind code of ref document: T Effective date: 20181024
2019-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2019-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190124 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190224 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190124 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2019-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190125 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190224
2019-07-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602008057621 Country of ref document: DE
2019-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2019-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20190514 Year of fee payment: 12
2019-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2019-08-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20190410 Year of fee payment: 12
2019-08-30	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2019-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2019-10-02	26N	No opposition filed	Effective date: 20190725
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2019-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20190529 Year of fee payment: 12
2019-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531
2020-02-05	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20190531
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190530
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2020-05-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190530
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531
2020-12-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602008057621 Country of ref document: DE
2021-01-15	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1185075 Country of ref document: HK
2021-03-31	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20200530
2021-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200530 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200531
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20201201 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080530 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181024

Publication	Publication Date	Title
EP2594562A3 (fr)	2013-08-14	Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
WO2006105501A3 (fr)	2007-05-31	Controle superieur de la glycemie dans le traitement du diabete
EA200900896A1 (ru)	2010-04-30	Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
WO2005012485A3 (fr)	2005-04-14	Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
FI2396005T3 (fi)	2026-01-20	Sglt2:n estäjä verensokeritasapainon parantamiseksi
TN2009000317A1 (en)	2010-12-31	Solid preparation comprising alogliptin and pioglitazone
WO2008108958A8 (fr)	2009-08-13	Dérivés de benzimidazole et leurs procédés d'utilisation
MX2010001784A (es)	2010-03-15	Activadores novedosos de la glucocinasa.
WO2009054423A1 (fr)	2009-04-30	Composé d'oxadiazolidinedione
WO2007120936A3 (fr)	2008-08-07	Utilisation de composés organiques
RU2533217C3 (ru)	2020-12-21	Препарат, содержащий инсулин, никотинамид и аминокислоту
JP2009137973A5 (fr)	2011-05-26
MY141034A (en)	2010-02-25	Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use
MX2007000406A (es)	2007-06-25	Solucion para infusion e inyeccion de levodopa.
NO20076425L (no)	2008-01-30	Fremgangsmater for behandling av drug-resistent cancer
MY152172A (en)	2014-08-15	Therapeutic agent for diabetes
TW200740452A (en)	2007-11-01	Therapeutic gastrodia extracts
WO2005113016A3 (fr)	2006-05-04	Modulation de l’expression de la glucose-6-phosphatase translocase
EA200870088A1 (ru)	2009-02-27	Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
WO2008061671A3 (fr)	2008-11-27	Utilisation d'un acide indazoleméthoxyalcanoïque dans la préparation d'une composition pharmaceutique
UA93581C2 (ru)	2011-02-25	средство, которое содержит G-CSF, для профилактики и лечения диабетической периферической невропатии
WO2003077949A3 (fr)	2004-03-25	Procedes relatifs au traitement du diabete par administration d'inhibiteurs de pde11a
WO2010056630A8 (fr)	2011-01-27	Triazolopyrimidinones et leurs méthodes d'utilisation
WO2005117913A3 (fr)	2006-03-16	Composition pharmaceutique ozonisee et procede associe
WO2007018687A8 (fr)	2010-02-04	Compositions et procédés destinés au traitement et à la prévention de conséquences sur la santé liées à l'hyperuricémie